JanOne has filed an international patent application for methods of using low dose naltrexone to treat chronic pain. JanOne is developing Jan123, a novel formulation of low dose naltrexone, to treat CRPS, an orphan disease with no current FDA-approved treatments. CRPS leaves patients in debilitating pain and suffering and, as a result, oftentimes patients resort to opioid pain medications.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>